Lung CancerMyLungHealthNCT06338592
The MyLungHealth Study Protocol: Engaging Patients to Enable Interoperable Lung Cancer Decision Support at Scale
A study testing MyLungHealth and DecisionPrecision+ in people with Lung Cancer and Lung Neoplasms/Diagnosis, run by University of Utah at 2 sites in United States.
Trial summary
Early lung cancer screening (LCS) through low-dose computed tomography (LDCT) is crucial but underused due to various barriers, including incomplete or inaccurate patient smoking data in the electronic health record and limited time for shared decision-making. Read more about this study
- Who is it for?
- Ages 50 to 79 years
- Conditions the study is for
- Lung Cancer, Lung Neoplasms/Diagnosis
- What is being tested?
- MyLungHealth and DecisionPrecision+
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 31,303 participants
- Where
- 2 sitesUnited States
- Study dates
- 28 Mar 2024to 28 Jan 2026
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 79 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- aged 50-79
- a history of smoking (e.g., current or former tobacco use)
- seen in a study primary care clinic in the 12 months preceding the start of the trial
- a 10-19 pack-year smoking history, an unknown pack-year history, unknown quit date for patients who quit smoking, or a 0 pack-year smoking history
- at least a 20 pack-year smoking history and are a current smoker or have quit within the last 15 years
Who cannot join
- >0 but < 10 pack-year smoking history or quit more than 15 years ago
- No use of the patient portal at least once in the year preceding the start of the study
- A lung cancer diagnosis at the start of the study
- LDCT completed in the past 3 years
- Another chest CT completed in the past year
- Structured EHR data indicating LCS SDM was provided in the past 3 years
- Exposed to the intervention during the pilot phase
- No visit at a study clinic during the trial period when the intervention was available
Trial locations and contacts
2 sites in 1 country.
United States2 sites
NYU Langone Health
New York, New York, 10016
University of Utah Health
Salt Lake City, Utah, 84112
About this study
Official title: The MyLungHealth Study Protocol: A Pragmatic Patient-Randomized Controlled Trial to Evaluate a Patient-Centered, Electronic Health Record-Integrated Intervention to Enhance Lung Cancer Screening in Primary Care
Early lung cancer screening (LCS) through low-dose computed tomography (LDCT) is crucial but underused due to various barriers, including incomplete or inaccurate patient smoking data in the electronic health record and limited time for shared decision-making. The objective of this trial is to investigate a patient-centered intervention, MyLungHealth, delivered through the patient portal. The intervention is designed to improve LCS rates through increased identification of eligible patients and informed decision making.
Read the detailed description
MyLungHealth is a multi-site pragmatic trial, involving University of Utah Health and New York University Langone Health primary care clinics. The MyLungHealth intervention was developed using a user-centered design process, informed by patient and provider focus groups and interviews. The intervention's effectiveness will be evaluated through a patient-randomized trial, comparing the combined use of MyLungHealth and DecisionPrecision+ (a provider-focused clinical decision support and shared decision-making intervention) against DecisionPrecision+ alone.
- Conditions
- Lung Cancer, Lung Neoplasms/Diagnosis
- Being tested
- MyLungHealth, DecisionPrecision+
- Medical subject headings
- Lung Neoplasms, Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MyLungHealthBehavioural
MyLungHealth is a patient-centered, EHR-integrated smoking data-quality improvement and education intervention. A key component of the MyLungHealth intervention is a pre-visit LCS eligibility questionnaire asked through the Epic EHR patient portal for individuals with unclear LCS eligibility due to missing or potentially inaccurate data in the EHR. Another key component of the MyLungHealth intervention is an interoperable, patient-centered educational app delivered through the EHR patient portal.
DecisionPrecision+Behavioural
DecisionPrecision+ is a multi-faceted intervention which includes provider-facing EHR preventive care reminders, a provider-facing EHR SDM tool, and simple patient-facing preventive care reminders.
| Study group | Role | What they receive |
|---|---|---|
| Study 1 (Study of Patients with Uncertain LCS Eligibility) Control Arm | No intervention | In Study 1 (Study of Patients with Uncertain LCS Eligibility), patients allocated to the control arm will not be exposed to the project intervention unless their EHR data change during the trial so that they have documented LCS eligibility. In these rare cases, these patients will be exposed to the intervention provided to patients in the control arm of Study 2 but will not be considered participants in Study 2. |
| Study 1 (Study of Patients with Uncertain LCS Eligibility) Intervention Arm | Experimental | Patients allocated to the intervention arm of Study 1 will be exposed to the MyLungHealth intervention in addition to usual care. The Study 1 MyLungHealth eligibility questionnaires will consist of pre-visit smoking history questions asked through the EHR patient portal to increase the identification of screening-eligible patients (Figure 2). Patients will be prompted to engage in the intervention through pre-visit questionnaires for primary care visits administered up to 7 days prior to the visits. These questions will ask about the patients' smoking history and determine whether patients meet LCS eligibility criteria. Study 1 patients who meet LCS eligibility criteria will be offered the intervention provided to patients in the intervention arm of Study 2 immediately after confirming eligibility but will not be considered participants in Study 2. Receives: Behavioral: MyLungHealth |
| Study 2 (Study of Patients with Documented LCS Eligibility) Control Arm | Active comparator | In Study 2 (Study of Patients with Documented LCS Eligibility), patients allocated to the control arm will be exposed to the DecisionPrecision+ intervention because DecisionPrecision+ intervention automatically identifies patients with documented LCS eligibility in the EHR. The DecisionPrecision+ intervention is designed to promote LCS and LCS SDM; the intervention consists of provider-facing EHR preventive care reminders, a provider-facing EHR SDM tool, and simple patient-facing preventive care reminders (only available at UUH). Simple patient-facing preventive care reminders will be available at UUH, but not NYU, because NYU does not use this type of reminders. Receives: Behavioral: DecisionPrecision+ |
| Study 2 (Study of Patients with Documented LCS Eligibility) Intervention Arm | Experimental | Patients allocated to the intervention arm will be offered the MyLungHealth education tool in addition to the DecisionPrecision+ intervention. The pre-visit questionnaire will directly invite patients to use the MyLungHealth education app, rather than first asking about smoking history to confirm eligibility. When patients affirm in the patient portal that they were able to successfully open the MyLungHealth education tool, their providers will be notified of their potential interest in LCS through a passive (non-interruptive) prompt in the EHR. Receives: Behavioral: MyLungHealth; Behavioral: DecisionPrecision+ |
What is being measured
The primary outcome is the main question the study is designed to answer.
Study 1 Primary Outcome: Count of Patients Newly Identified as Eligible for Lung Cancer Screening
In Study 1, the primary outcome was the number of patients newly identified as eligible for lung cancer screening during the 12-month follow-up period, defined as having a smoking history of at least 20 pack-years and being a current smoker or having quit within the past 15 years, based on structured electronic health record data and patient-reported smoking history collected through the MyLungHealth patient portal.
Measured: 1 year trial period
Study 2 Primary Outcome: Count of Participants for Whom LDCT Was Ordered.
In Study 2, which enrolled participants with documented lung cancer screening eligibility at baseline, the primary outcome was the count of participants for whom a low-dose computed tomography (LDCT) lung cancer screening order was placed during the 12-month follow-up period, as identified from structured electronic health record order data.
Measured: 1 year trial period
Secondary outcomes (4)
Study 1 Secondary Outcome: Count of Participants for Whom LDCT Eligibility Status Became Known.
In Study 1, which enrolled participants with uncertain lung cancer screening eligibility at baseline, a secondary outcome was the count of participants for whom lung cancer screening eligibility status became known during the 12-month follow-up period, based on structured electronic health record data and patient-reported smoking history collected through the MyLungHealth patient portal.
Measured: 1 year trial period
Study 1 Secondary Outcome: Count of Participants for Whom LDCT Was Ordered.
Secondary outcomes for Study 1 will be the count of participants for whom LDCT was ordered during the 1-year trial.
Measured: 1 year trial period
Study 1 Secondary Outcome: Count of Participants for Whom LDCT Was Completed.
Secondary outcomes for Study 1 will be the percentage of participants for whom LDCT was completed during the 1-year trial.
Measured: 1 year trial period
Study 2 Secondary Outcome: Count of Participants for Whom LDCT Was Completed.
A secondary outcome for Study 2 will be the percentage of participants for whom LDCT was completed during the 1-year trial.
Measured: 1 year trial period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Mar 2024
- Study start28 Mar 2024
- Primary completion27 Mar 2025
- Study completion28 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a patient randomized trial that includes two sub-studies, with 2 arms each.
- Masking
- None (open label)
- Enrolment
- 31,303 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Utah
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kensaku Kawamoto, MD, PhD, MHS, University of Utah
- Investigators
- Kensaku Kawamoto, MD, PhD, MHS, Principal investigator, University of Utah
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06338592
- Sponsor's protocol ID
- UUtah_00153806
- Acronym
- MyLungHealth
- Status last verified
- Mar 2026
- First submitted
- 18 Mar 2024
- Last updated
- 27 Mar 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: On completion, study data will be made available in compliance with institutional and sponsor data sharing policies.
Publications
Kukhareva PV, Li H, Caverly TJ, Del Fiol G, Fagerlin A, Butler JM, Hess R, Zhang Y, Taft T, Flynn MC, Reddy C, Martin DK, Warner IA, Rodriguez-Loya S, Warner PB, Kawamoto K. Implementation of Lung Cancer Screening in Primary Care and Pulmonary Clinics: Pragmatic Clinical Trial of Electronic Health Record-Integrated Everyday Shared Decision-Making Tool and Clinician-Facing Prompts. Chest. 2023 Nov;164(5):1325-1338. doi: 10.1016/j.chest.2023.04.040. Epub 2023 May 3.
PubMed 37142092Balbin CA, Stevens L, Dalrymple R, Tiase VL, Kaphingst KA, Stevens ER, Kukhareva PV, Caverly TJ, Del Fiol G, Mann D, Kwon J, Fagerlin A, Butler JM, Kawamoto K. MyLungHealth, a Patient-Facing Education Tool for Lung Cancer Screening: Qualitative User-Centered Design Study. JMIR Form Res. 2026 May 21;10:e83033. doi: 10.2196/83033.
PubMed 42166800Kukhareva PV, Li H, Balbin C, Stevens ER, Mann DM, Butler JM, Caverly TJ, Del Fiol G, Kaphingst KA, Schlechter CR, Tiase VL, Fagerlin A, Zhang Y, Hess R, Flynn MC, Reddy C, Martin D, Warner PB, Nanjo C, Choi J, Ngo-Metzger Q, Kawamoto K. Enhancement of Patient-Centered Lung Cancer Screening: The MyLungHealth Randomized Clinical Trial. JAMA Oncol. 2026 Feb 1;12(2):167-176. doi: 10.1001/jamaoncol.2025.5672.
PubMed 41452617Kukhareva P, Balbin C, Stevens E, Mann D, Tiase V, Butler J, Del Fiol G, Caverly T, Kaphingst K, Schlechter CR, Fagerlin A, Li H, Zhang Y, Hess R, Flynn M, Reddy C, Warner P, Choi J, Martin D, Nanjo C, Metzger Q, Kawamoto K. The MyLungHealth study protocol: a pragmatic patient-randomised controlled trial to evaluate a patient-centred, electronic health record-integrated intervention to enhance lung cancer screening in primary care. BMJ Open. 2024 Dec 22;14(12):e087056. doi: 10.1136/bmjopen-2024-087056.
PubMed 39806641
Study at a glance
From the registry record, last updated by the sponsor on 27 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The MyLungHealth Study Protocol: A Pragmatic Patient-Randomized Controlled Trial to Evaluate a Patient-Centered, Electronic Health Record-Integrated Intervention to Enhance Lung Cancer Screening in Primary Care
- ClinicalTrials.gov ID
- NCT06338592
- Acronym / sponsor ID
- MyLungHealth / UUtah_00153806
- Conditions
- Lung Cancer, Lung Neoplasms/Diagnosis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 31,303 participants (actual)
- Lead sponsor
- University of UtahUniversity, hospital or other
- Study start
- 28 Mar 2024 (actual)
- Primary completion
- 27 Mar 2025 (actual)
- Study completion
- 28 Jan 2026 (actual)
- First posted
- 29 Mar 2024 (actual)
- Results
- Posted 27 Mar 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Early lung cancer screening (LCS) through low-dose computed tomography (LDCT) is crucial but underused due to various barriers, including incomplete or inaccurate patient smoking data in the electronic health record and limited time for shared decision-making. The objective of this trial is to investigate a patient-centered intervention, MyLungHealth, delivered through the patient portal. The intervention is designed to improve LCS rates through increased identification of eligible patients and informed decision making.
Detailed description
MyLungHealth is a multi-site pragmatic trial, involving University of Utah Health and New York University Langone Health primary care clinics. The MyLungHealth intervention was developed using a user-centered design process, informed by patient and provider focus groups and interviews. The intervention's effectiveness will be evaluated through a patient-randomized trial, comparing the combined use of MyLungHealth and DecisionPrecision+ (a provider-focused clinical decision support and shared decision-making intervention) against DecisionPrecision+ alone.
Study design
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
- Model description
- This is a patient randomized trial that includes two sub-studies, with 2 arms each.
| Arm | Type | Receives |
|---|---|---|
| Study 1 (Study of Patients with Uncertain LCS Eligibility) Control Arm | No intervention | –In Study 1 (Study of Patients with Uncertain LCS Eligibility), patients allocated to the control arm will not be exposed to the project intervention unless their EHR data change during the trial so that they have documented LCS eligibility. In these rare cases, these patients will be exposed to the intervention provided to patients in the control arm of Study 2 but will not be considered participants in Study 2. |
| Study 1 (Study of Patients with Uncertain LCS Eligibility) Intervention Arm | Experimental | Behavioral: MyLungHealthPatients allocated to the intervention arm of Study 1 will be exposed to the MyLungHealth intervention in addition to usual care. The Study 1 MyLungHealth eligibility questionnaires will consist of pre-visit smoking history questions asked through the EHR patient portal to increase the identification of screening-eligible patients (Figure 2). Patients will be prompted to engage in the intervention through pre-visit questionnaires for primary care visits administered up to 7 days prior to the visits. These questions will ask about the patients' smoking history and determine whether patients meet LCS eligibility criteria. Study 1 patients who meet LCS eligibility criteria will be offered the intervention provided to patients in the intervention arm of Study 2 immediately after confirming eligibility but will not be considered participants in Study 2. |
| Study 2 (Study of Patients with Documented LCS Eligibility) Control Arm | Active comparator | Behavioral: DecisionPrecision+In Study 2 (Study of Patients with Documented LCS Eligibility), patients allocated to the control arm will be exposed to the DecisionPrecision+ intervention because DecisionPrecision+ intervention automatically identifies patients with documented LCS eligibility in the EHR. The DecisionPrecision+ intervention is designed to promote LCS and LCS SDM; the intervention consists of provider-facing EHR preventive care reminders, a provider-facing EHR SDM tool, and simple patient-facing preventive care reminders (only available at UUH). Simple patient-facing preventive care reminders will be available at UUH, but not NYU, because NYU does not use this type of reminders. |
| Study 2 (Study of Patients with Documented LCS Eligibility) Intervention Arm | Experimental | Behavioral: MyLungHealth, Behavioral: DecisionPrecision+Patients allocated to the intervention arm will be offered the MyLungHealth education tool in addition to the DecisionPrecision+ intervention. The pre-visit questionnaire will directly invite patients to use the MyLungHealth education app, rather than first asking about smoking history to confirm eligibility. When patients affirm in the patient portal that they were able to successfully open the MyLungHealth education tool, their providers will be notified of their potential interest in LCS through a passive (non-interruptive) prompt in the EHR. |
Who may qualify
- Ages
- 50 to 79 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- aged 50-79
- a history of smoking (e.g., current or former tobacco use)
- seen in a study primary care clinic in the 12 months preceding the start of the trial
- a 10-19 pack-year smoking history, an unknown pack-year history, unknown quit date for patients who quit smoking, or a 0 pack-year smoking history
- at least a 20 pack-year smoking history and are a current smoker or have quit within the last 15 years
Key exclusion criteria (8 listed)
- >0 but < 10 pack-year smoking history or quit more than 15 years ago
- No use of the patient portal at least once in the year preceding the start of the study
- A lung cancer diagnosis at the start of the study
- LDCT completed in the past 3 years
- Another chest CT completed in the past year
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MyLungHealthMyLungHealth is a patient-centered, EHR-integrated smoking data-quality improvement and education intervention. A key component of the MyLungHealth intervention is a pre-visit LCS eligibility questionnaire asked through the Epic EHR patient portal for individuals with unclear LCS eligibility due to missing or potentially inaccurate data in the EHR. Another key component of the MyLungHealth intervention is an interoperable, patient-centered educational app delivered through the EHR patient portal. | Behavioural | Study 1 (Study of Patients with Uncertain LCS Eligibility) Intervention Arm, Study 2 (Study of Patients with Documented LCS Eligibility) Intervention Arm |
| DecisionPrecision+DecisionPrecision+ is a multi-faceted intervention which includes provider-facing EHR preventive care reminders, a provider-facing EHR SDM tool, and simple patient-facing preventive care reminders. | Behavioural | Study 2 (Study of Patients with Documented LCS Eligibility) Control Arm, Study 2 (Study of Patients with Documented LCS Eligibility) Intervention Arm |
Primary outcome
Study 1 Primary Outcome: Count of Patients Newly Identified as Eligible for Lung Cancer Screening
Time frame: 1 year trial period
In Study 1, the primary outcome was the number of patients newly identified as eligible for lung cancer screening during the 12-month follow-up period, defined as having a smoking history of at least 20 pack-years and being a current smoker or having quit within the past 15 years, based on structured electronic health record data and patient-reported smoking history collected through the MyLungHealth patient portal.
Study 2 Primary Outcome: Count of Participants for Whom LDCT Was Ordered.
Time frame: 1 year trial period
In Study 2, which enrolled participants with documented lung cancer screening eligibility at baseline, the primary outcome was the count of participants for whom a low-dose computed tomography (LDCT) lung cancer screening order was placed during the 12-month follow-up period, as identified from structured electronic health record order data.
4 secondary outcomes
Study 1 Secondary Outcome: Count of Participants for Whom LDCT Eligibility Status Became Known.
Time frame: 1 year trial period
Study 1 Secondary Outcome: Count of Participants for Whom LDCT Was Ordered.
Time frame: 1 year trial period
Study 1 Secondary Outcome: Count of Participants for Whom LDCT Was Completed.
Time frame: 1 year trial period
Study 2 Secondary Outcome: Count of Participants for Whom LDCT Was Completed.
Time frame: 1 year trial period
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 37142092Kukhareva PV, Li H, Caverly TJ, Del Fiol G, Fagerlin A, Butler JM, Hess R, Zhang Y, Taft T, Flynn MC, Reddy C, Martin DK, Warner IA, Rodriguez-Loya S, Warner PB, Kawamoto K. Implementation of Lung Cancer Screening in Primary Care and Pulmonary Clinics: Pragmatic Clinical Trial of Electronic Health Record-Integrated Everyday Shared Decision-Making Tool and Clinician-Facing Prompts. Chest. 2023 Nov;164(5):1325-1338. doi: 10.1016/j.chest.2023.04.040. Epub 2023 May 3.
- Derived from this study: PubMed 42166800Balbin CA, Stevens L, Dalrymple R, Tiase VL, Kaphingst KA, Stevens ER, Kukhareva PV, Caverly TJ, Del Fiol G, Mann D, Kwon J, Fagerlin A, Butler JM, Kawamoto K. MyLungHealth, a Patient-Facing Education Tool for Lung Cancer Screening: Qualitative User-Centered Design Study. JMIR Form Res. 2026 May 21;10:e83033. doi: 10.2196/83033.
- Derived from this study: PubMed 41452617Kukhareva PV, Li H, Balbin C, Stevens ER, Mann DM, Butler JM, Caverly TJ, Del Fiol G, Kaphingst KA, Schlechter CR, Tiase VL, Fagerlin A, Zhang Y, Hess R, Flynn MC, Reddy C, Martin D, Warner PB, Nanjo C, Choi J, Ngo-Metzger Q, Kawamoto K. Enhancement of Patient-Centered Lung Cancer Screening: The MyLungHealth Randomized Clinical Trial. JAMA Oncol. 2026 Feb 1;12(2):167-176. doi: 10.1001/jamaoncol.2025.5672.
- Derived from this study: PubMed 39806641Kukhareva P, Balbin C, Stevens E, Mann D, Tiase V, Butler J, Del Fiol G, Caverly T, Kaphingst K, Schlechter CR, Fagerlin A, Li H, Zhang Y, Hess R, Flynn M, Reddy C, Warner P, Choi J, Martin D, Nanjo C, Metzger Q, Kawamoto K. The MyLungHealth study protocol: a pragmatic patient-randomised controlled trial to evaluate a patient-centred, electronic health record-integrated intervention to enhance lung cancer screening in primary care. BMJ Open. 2024 Dec 22;14(12):e087056. doi: 10.1136/bmjopen-2024-087056.
- Individual participant dataSharing planned: No. On completion, study data will be made available in compliance with institutional and sponsor data sharing policies.
Related trials for Lung Cancer
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
RecruitingPhase 2/3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 3
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Non-small Cell Lung Cancer
Recruiting
More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)
Acute Lymphatic Leukemia, Lymphoma
RecruitingPhase 1
SW-682 in Advanced Solid Tumors
Advanced Solid Tumor, Mesothelioma, Malignant
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kensaku Kawamoto, MD, PhD, MHS principal investigator
University of Utah
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MyLungHealth and DecisionPrecision+ in people with Lung Cancer and Lung Neoplasms/Diagnosis, run by University of Utah at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 27 Mar 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Study 1 Primary Outcome: Count of Patients Newly Identified as Eligible for Lung Cancer Screening (time frame: 1 year trial period). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06338592, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.